Advertisement

Advertisement

ADVERTISEMENT

Videos

Abiraterone vs Docetaxel for De Novo Prostate Cancer in Real-World and Trial Settings

Videos

Abiraterone vs Docetaxel for De Novo Prostate Cancer in Real-World and Trial Settings

03/18/2021

Daniel Geynisman, MD, discusses results from a study which compared real-world survival among men with de novo metastatic prostate cancer treated with abiraterone acetate or docetaxel and compared these outcomes to those seen in clinical...

Daniel Geynisman, MD, discusses results from a study which compared real-world survival among men with de novo metastatic prostate cancer treated with abiraterone acetate or docetaxel and compared these outcomes to those seen in clinical...

Daniel Geynisman, MD, discusses...

03/18/2021

Journal of Clinical Pathways

Patterns and Predictors of Oral Anticancer Agent Use for Metastatic RCC

Videos

Patterns and Predictors of Oral Anticancer Agent Use for Metastatic RCC

03/18/2021

03/18/2021

Journal of Clinical Pathways

Treatment Patterns After PD1/L1 Inhibitor Discontinuation in Advanced Urothelial Carcinoma

Videos

Treatment Patterns After PD1/L1 Inhibitor Discontinuation in Advanced Urothelial Carcinoma

03/18/2021

03/18/2021

Journal of Clinical Pathways

Real-World Treatment Sequences After First-Line Therapy in Metastatic RCC

Videos

Real-World Treatment Sequences After First-Line Therapy in Metastatic RCC

03/18/2021

03/18/2021

Journal of Clinical Pathways

Higher Hospital Competition Associated With Improved Quality of Prostate Cancer Care

Videos

Higher Hospital Competition Associated With Improved Quality of Prostate Cancer Care

03/18/2021

03/18/2021

Journal of Clinical Pathways

Real-World Survival Trends in Muscle-Invasive Bladder Cancer and Urothelial Carcinoma

Videos

Real-World Survival Trends in Muscle-Invasive Bladder Cancer and Urothelial Carcinoma

03/12/2021

Nimira Alimohamed, MD, discusses results from a real-world analysis of outcomes over time in patients with muscle-invasive bladder cancer and patients with metastatic urothelial carcinoma.

Nimira Alimohamed, MD, discusses results from a real-world analysis of outcomes over time in patients with muscle-invasive bladder cancer and patients with metastatic urothelial carcinoma.

Nimira Alimohamed, MD, discusses...

03/12/2021

Journal of Clinical Pathways

Real-World Ibrutinib Dose Reductions, Discontinuations in CLL

Videos

Real-World Ibrutinib Dose Reductions, Discontinuations in CLL

03/11/2021

Jing-Zhou Hou, MD, PhD, discusses dose reductions and discontinuations between patients with CLL receiving ibrutinib in the community vs academic settings.

Jing-Zhou Hou, MD, PhD, discusses dose reductions and discontinuations between patients with CLL receiving ibrutinib in the community vs academic settings.

Jing-Zhou Hou, MD, PhD,...

03/11/2021

Journal of Clinical Pathways

All4Cure: Patient Data Aggregate Platform for Collaborative Multiple Myeloma Care

Videos

All4Cure: Patient Data Aggregate Platform for Collaborative Multiple Myeloma Care

03/05/2021

Tony Blau, MD, Founder and CEO, provides a demonstration of All4Cure, discusses the vision and need for the platform, and describes its ability to improve patient care.

Tony Blau, MD, Founder and CEO, provides a demonstration of All4Cure, discusses the vision and need for the platform, and describes its ability to improve patient care.

Tony Blau, MD, Founder and CEO,...

03/05/2021

Journal of Clinical Pathways

Neoadjuvant Immune Checkpoint Inhibitors Unlikely Cost-Effective for Muscle-Invasive Bladder Cancer

Videos

Neoadjuvant Immune Checkpoint Inhibitors Unlikely Cost-Effective for Muscle-Invasive Bladder Cancer

02/25/2021

02/25/2021

Journal of Clinical Pathways

Impact of Oral Anticancer Agent Adherence on Survival Outcomes in Metastatic RCC

Videos

Impact of Oral Anticancer Agent Adherence on Survival Outcomes in Metastatic RCC

02/25/2021

02/25/2021

Journal of Clinical Pathways

Specialties

Prostate Cancer

JCP May/June 2024 Issue

Current Issue

June 2024

Volume 10

Issue 3

More Content

Blogs

Popular Articles

Conference Coverage

American Society of Clinical Oncology (ASCO) 2016 Annual Meeting

05/31/2016

Its once again time for the American Society of Clinical Oncology (ASCO) Annual Meeting (June 3-7, 2016; Chicago, IL), which will bring together more than 30,000 oncology professionals from around the world to...

Its once again time for the American Society of Clinical Oncology (ASCO) Annual Meeting (June 3-7, 2016; Chicago, IL), which will bring together more than 30,000 oncology professionals from around the world to...

Its...

05/31/2016

Journal of Clinical Pathways

Editor's Page

For Buy-In of the Clinical Pathways Concept, Transparency Is Key

05/06/2016

Winston Wong, PharmD, Editor-in-Chief

Essential to the success of clinical pathways is transparency of the development process. This includes transparency regarding the clinical evidence reviewed, the economic evaluations made, and the process by which...

Essential to the success of clinical pathways is transparency of the development process. This includes transparency regarding the clinical evidence reviewed, the economic evaluations made, and the process by which...

...

05/06/2016

Journal of Clinical Pathways

Pharma Insights

When Medication Price Deflates Perception of Therapeutic Effect

04/11/2016

Larry Blandford, PharmD—Column Editor

Stephen C Carter

Manufacturers set prices for their products that best represent their value while providing the greatest financial return on investment. Thus, conventional wisdom would suggest that manufacturers set a higher price...

Manufacturers set prices for their products that best represent their value while providing the greatest financial return on investment. Thus, conventional wisdom would suggest that manufacturers set a higher price...

...

04/11/2016

Journal of Clinical Pathways

Research in Review

Report Outlines the Path to Improving Biomarker Tests for Targeted Therapies

03/21/2016

JCP Editors

Biomarker tests are not being adequately used in clinical practice due to a lack of common evidentiary standards for regulatory, reimbursement, and clinical decisions regarding their use, according to a report by the...

Biomarker tests are not being adequately used in clinical practice due to a lack of common evidentiary standards for regulatory, reimbursement, and clinical decisions regarding their use, according to a report by the...

...

03/21/2016

Journal of Clinical Pathways

Research in Review

Costs for High-Risk Patients With ALL Increasing

02/25/2016

JCP Editors

Costs for high-risk pediatric and adolescent patients with acute lymphoblastic leukemia (ALL) may be higher than standard-risk patients with the disease, according to a recent study. While data regarding health care...

Costs for high-risk pediatric and adolescent patients with acute lymphoblastic leukemia (ALL) may be higher than standard-risk patients with the disease, according to a recent study. While data regarding health care...

Costs...

02/25/2016

Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement